LOGO

Checklist: New Hope On The Horizon

Regeneron and AstraZeneca join forces in the battle to end obesity and related diseases.
Posted on Oct 6, 2021 | 05:00pm
Brought to you by Watch

Regeneron and AstraZeneca have teamed up to ramp up research and develop new treatments to combat obesity, and to fortify the fight against obesity-related diseases that can cause death. Regeneron, a leader in genetics and human biology, and AstraZeneca, a leader in chemistry and small molecule biology, create a powerful duo, and they’re determined to make a difference.

The truth is obesity is associated with many serious health complications and it can lead to organ dysfunction, including in the heart, liver, kidneys, and pancreas. Today, the prevalence of obesity has more than tripled since 1975, and approximately 650 million adults all over the world are struggling with obesity.

In a serious effort to turn the tide on this trend, Regeneron and AstraZeneca have brought their respective expertises to the table, and made an historic agreement to share equally in the costs of R&D and any potential profits. "The next era of medicine is being fueled by important genetics findings that direct drug developers on how to deploy our toolkit of biologics, small molecules and gene editing technologies in order to safely help patients in need," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron Pharmaceuticals Inc. regeneron.comastrazeneca.com

Photo Credit: Getty Images